Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation

Documenti analoghi

• The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
  di: Obada Ababneh, et al.
  Pubblicazione: (2022-05-01)
• Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation
  di: Nathalie Forgeard, et al.
  Pubblicazione: (2022-07-01)
• Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia
  di: Benjamin M. Heyman, et al.
  Pubblicazione: (2025-02-01)
• Utility of Bruton’s Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia)
  di: Maroun Bou Zerdan, et al.
  Pubblicazione: (2022-01-01)
• WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
  di: Maddalena Mazzucchelli, et al.
  Pubblicazione: (2018-01-01)